There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has
been a remarkable increase in approved nano-based pharmaceutical products. These novel …

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …

Nausea and vomiting are still considered to be two of the most troublesome adverse events
(AEs) for patients treated with antineoplastic therapy. To optimise the utility of available …

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant
deterioration in quality of life and is perceived by patients as a major adverse effect of the …

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …

Background Olanzapine 10 mg added to standard antiemetic therapy including aprepitant,
palonosetron, and dexamethasone has been recommended for the prevention of …

Background Cannabis has a long history of medicinal use. Cannabis‐based medications
(cannabinoids) are based on its active element, delta‐9‐tetrahydrocannabinol (THC), and …

Purpose To update the American Society of Clinical Oncology (ASCO) guideline for
antiemetics in oncology. Methods A systematic review of the medical literature was …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis
address all aspects of management for chemotherapy-induced nausea and vomiting. These …